Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

Symbiotec Pharmalab is set to raise capital through an IPO, with plans to issue ₹150 crore for debt repayment and an additional ₹1,607 crore through an offer for sale. This will reduce the promoter group's stake from 36.4% to 33.3%. The company specializes in active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products, with over two-thirds of revenue coming from international markets, particularly Europe.

The company's valuation appears attractive when compared to its peers. Its global leadership in corticosteroid and steroidal-hormone APIs is evident, with a market share of 38.2% and 23.8% respectively in FY26. This dominance is backed by a backward-integrated platform, backed by approvals from major regulatory bodies worldwide.

APIs continue to be the primary revenue generator, accounting for more than 96% of total revenue in FY26. However, the company is also venturing into newer areas such as complex injectables and contract manufacturing (CDMO) services. Despite heavy capital expenditure and fluctuations in working capital, the company has seen a steady growth in revenue, annualized at 10.2% from FY24 to FY26. The operating profit, EBITDA, and net profit have also seen positive growth over the same period.

However, investors should note that Symbiotec Pharmalab does not have an exact listed peer due to its niche in steroidal hormones and advanced drug-device formulation. Therefore, a price-earnings (P/E) multiple of up to 58 has been suggested for the company. The P/E range for other API or biotechnology manufacturers is between 63 and 110, suggesting that Symbiotec Pharmalab's valuation may be more favorable. Hence, high-risk investors may find this IPO appealing, given the company's market leadership and growth prospects.